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Maternal and neonatal outcome
A B S T R A C T
Thrombotic Microangiopathies during pregnancy and puerperium are very rare and, if undiagnosed, can
be lifethreating. Pregnancy and postpartum can represent a trigger in predisposed patients. Therefore,
obstetricians are usually the first to observe clinical symptoms and laboratory abnormalities suggestive
of Thrombotic Microangiopathies.
The aim of this review is to briefly describe the obstetrical and perinatal outcome of these entities and
highlight the clues for a correct diagnosis of pregnancy-related Thrombotic Microangiopathies.
© 2019 Elsevier B.V. All rights reserved.
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Thrombotic microangiopathies (TMAs) are rare, severe
conditions associated with serious morbidity and up to 90%
mortality rate, if untreated. Prompt recognition and initiation of
early specific therapy reduces substantially mortality rate to
10%–20% [1].
The term "thrombotic microangiopathy" defines a pathologic
modification of the microvasculature, with detachment or swelling
of the endothelium and luminal platelet aggregation leading to* Corresponding author.
E-mail address: laura.sarno@unina.it (L. Sarno).
https://doi.org/10.1016/j.ejogrb.2019.03.018
0301-2115/© 2019 Elsevier B.V. All rights reserved.impairment of vessel microcirculation. The clinical consequences
of these disorders are thrombocytopenia, mechanical haemolytic
anemia and ischemic injuries to different organs, particularly
affecting central nervous system and kidneys [2].
There is a wide range of diseases that can present with a
microangiopathic phenotype; their laboratory features almost
uniformly include thrombocytopenia and hemolytic anemia with
evidence of red blood cell fragmentation, also identified as
microangiopathic hemolytic anemia (MAHA) [2].
The two vulnerable periods that can act as trigger for
development of TMAs are pregnancy and puerperium. Indeed,
there is an immune adaptation during pregnancy, called
materno-placental immune tolerance, characterized by an
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the adaptive immune system. [3] The complement system has a
central role in the innate immune system and its activation is
controlled by several regulators in order to prevent an over-
activation. An imbalance in its regulation can result in
inflammation and thrombosis.
Pregnancy-related TMAs are rare conditions, with an incidence
of 1:25,000 births [4]. However, they represent an obstetrical
emergency and appropriate interventions are necessary to
improve maternal and fetal outcomes. Therefore, differential
diagnosis among pregnancy-related TMAs is crucial to ensure a
correct management. In these cases, a cooperation of the
multidisciplinary team (obstetrician, neonatologist hematologist,
anesthesiologist, nephrologist and immunologist) is a cornerstone.
The aim of this review is not only to briefly describe obstetrical
and perinatal outcomes of these entities, but also to highlight the
clues for a correct diagnosis of pregnancy-related TMAs.
Classification of TMAs in pregnancy
There is an international consensus in defining under the name
of TMAs three different conditions that can develop during
pregnancy or puerperium: Haemolysis, Elevated Liver enzymes
and Low Platelets (HELLP) syndrome, Thrombotic Thrombocyto-
penic Purpura (TTP) and atypical Hemolytic Uremic Syndrome
(aHUS).
HELLP syndrome
The acronym HELLP defines a condition characterized by
haemolysis (H), elevated liver enzymes (EL), low platelet count
(LP).
HELLP syndrome is the most common pregnancy specific TMA
condition occurring in 0,2-0,6% of pregnancies [5]. A mortality rate
ranging from 1 to 4% has been previously reported [6,7]; morbidity
is related to complications, such as pulmonary edema, acute
kidney injury (AKI), disseminated intravascular coagulation (DIC),
placental abruption, liver hemorrhage, adult respiratory distress
syndrome, stroke or sepsis [5].
Clinical symptoms include upper abdominal pain and tender-
ness, nausea, vomiting, headache and jaundice. Abdominal
symptoms are more typical compared to other TMAs, but also
neurological and renal damage can be present.
Although the pathogenesis of HELLP is believed to be on the
spectrum of preeclampsia via abnormal placentation, endothelial
dysfunction, and release of vasoactive substances in the first
trimester, the cellular biology and natural history of the disease
that results in its distinct phenotype is not well defined.
Recent evidence highlights complement activation in its
pathogenesis. It has been postulated an up-regulation of the
alternative pathway of complement using markers in serum and
urine (C5b-9 or membrane attack complex/MAC) [8] and
mutations in the activated protein C (APC) have been found in
up to 20% of HELLP patients [9].
HELLP occurs typically during the third trimester, but it has
reported to complicate pregnancy during the second trimester in
up to 11% of cases. Pregnancy triggers HELLP in 69% of cases, while
the rest of the cases appear postpartum, usually within 48 h after
delivery [6].
Renal involvement and acute kidney injury (AKI) is observed
in up to 40% of cases in otherwise healthy pregnant women [10],
and progresses to end-stage renal disease (ESRD) in 10–30% of
cases [11].
Maternal mortality in AKI HELLP-related is reported to be 13% in
a large prospective study conducted in the US on 442 pregnant
women [6]. In the same study, 20% of postpartum HELLP caseswere complicated by AKI and often required dialysis [6]. Gul et al
reported that, even if perinatal mortality and neonatal morbidity-
mortality were similar in HELLP syndrome compared with severe
preeclampsia-eclampsia without HELLP, overall stillbirth was
higher in HELLP syndrome with no regular prenatal care and
reported to be as high as 10,3% [12]. The neonatal mortality rate has
been reported to be 19,5%, compared to 2% in normotensive
subjects [13].
Thrombotic Thrombocytopenic Purpura (TTP)
TTP is a rare, life-threatening TMA characterized by severe
deficiency in ADAMTS-13 (A Disintegrin And Metalloprotease with
ThromboSpondin type 1 domain 13). Pregnancy is a known trigger
of TTP; partly due to the physiological decrease of ADAMTS-13
activity, while its substrate, von Willerbrand Factor (vWF),
increases [14].
Overall, the estimated incidence of TTP associated with
pregnancy is less than 1 per 100,000 pregnancies [15], even if a
retrospective study on 8908 deliveries in a tertiary unit reported
that the prevalence of TTP among thrombocytopenic pregnant
women was up to 5% [16].
There were 4 pregnancies in this cohort. Regarding perinatal
outcome, there were two neonatal deaths due to the prematurity
and aorta coarctation. The other two infants were also born
prematurely, but the outcome was uneventful.
There are two types of TTP during pregnancy: acquired,
antibody mediated TTP and late onset congenital TTP, presenting
as de novo in pregnancy. In women with acquired TTP, there is an
evidence of anti-ADAMTS 13 IgG antibodies [17], while late onset
congenital TTP has been reported to represent up to 66% of TTP
unmasked during pregnancy [18]. It can occur anytime during
pregnancy, but the risk is greater in the second and third trimester.
Women with intrauterine fetal death or those with previous fetal
loss or severe growth restriction have an increased risk [19].
Clinical presentation of congenital and acquired TTP are
similar. Typical features of TTP are mainly neurological
symptoms, but elevated troponin levels and renal impairment
may also be present. Although previous studies described a
typical pentad of symptoms suggestive of TTP: fever, hemolytic
anemia, thrombocytopenia, renal impairment, and neurologic
manifestations, recent studies reported this pentad to be
present only in 5–40% of cases of TTP [20]. Fever seems to be
quite uncommon and other reported symptoms are nausea,
vomiting, diarrhea, abdominal pain, weakness and bleeding. In
general, platelets count is between 20,000 and 50000/mm3 at
presentation but it can range between 5000 and 120000/mm3
[1]. The most common complication is the relapse of the
condition, reported in up to 36% of cases [21]. If untreated, the
reported mortality may reach 90% [1].
Atypical Hemolytic Uremic Syndrome (aHUS)
aHUS is a rare genetic disorder characterized by complement-
mediated TMA resulting from mutations affecting the regulation of
the alternative complement pathway. Typical manifestations are
hemolytic anemia, thrombocytopenia and renal impairment.
According to the “multiple-hit” hypothesis [22], aHUS is a
consequence of both genetic predisposition to alternative comple-
ment dysregulation and occurrence of events or conditions that
may precipitate TMA by activating complement and/or damaging
the endothelium. Complement-amplifying conditions, such as
pregnancy and its complications (preeclampsia, HELLP), may be
comorbid with aHUS, unmasking a previously undiagnosed case, or
leading to a misdiagnosis [23]. Moreover, aHUS may occasionally
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differentiate between those conditions.
Pregnancy can unmask aHUS in patients with genetic
susceptibility. A French retrospective study reported that in a
cohort of 100 adult female aHUS patients, about 20% of cases were
pregnancy-related.
Of all pregnancy-related aHUS, 70–80% of cases presents in the
postpartum period [24]. Indeed, the production of complement
regulating proteins by the placenta terminates after delivery [25].
The risk for pregnancy associated aHUS was highest during a
second pregnancy in this cohort. [26] A subsequent French study
reported that among 87 patients with pregnancy-associated HUS,
76% developed in the postpartum period and 58% during the first
pregnancy [27].
On contrary, a retrospective study by Huerta et al from the
Spanish aHUS Registry reported that majority (16/22) of patients
with pregnancy related aHUS presented during the first pregnancy
[24]. In the Austrian cohort, out of the 7 patients who presented
aHUS during or soon after the pregnancy, 5 (71,4%) developed
aHUS during the first pregnancy [28].
There are several gene mutations related to susceptibility to the
disease; these mutations lead to loss of function of several
complement regulatory proteins. However, the disease can
develop also without any known mutation and the penetrance
of complement-aHUS has been found to be only approximately
50% [29].
There is an emerging evidence that clinical manifestations and
prognosis of the aHUS is strongly related to the genotype involved
[25]. The influence of each complement abnormality on clinical
characteristics and prognosis of aHUS are discussed in details in a
review by Yoshida et al. [30] This may be the reason for different
outcomes in different cohorts.
While most of the studies in women with aHUS included non-
pregnant patients, studies describing pregnancy related aHUS are
relatively rare and focused more on the maternal than the neonatal
outcome. French cohort reported no differences in outcomes,
comparing patients with pregnancy- related and non- pregnancy-
related aHUS [26].
Women carrying genetic mutations are more likely to have
preeclampsia compared to the general population (7,7% vs 2–5%).
However, majority of pregnancies are uneventful [25].Fig. 1. Laboratory changes and clinical symptoms related to TMAs.
ULN (Upper limit of the normal).In the Spanish cohort, of six patients that developed aHUS prior
to delivery, three delivered near term, one at 32 weeks and one at
24 weeks. The last case had therapeutic abortion due to the fetal
hydrops, probably not related to the aHUS. The French cohort
reported 4.8% of fetal loss, but no details were provided. The
Vienna Thrombotic Microangiopathy Cohort retrospectively and
prospectively investigated 27 maternal and fetal pregnancy
outcomes in 14 women with aHUS. Twenty-one pregnancies
(78%) resulted in a live birth, two preterm stillborn and four
pregnancies ended up with early spontaneous abortions. Thereaf-
ter, nine pregnancies of four women were prospectively followed;
six of these pregnancies were treated with prophylactic plasma
infusions. Of those, one pregnancy resulted in intrauterine fetal
death and seven pregnancies were uneventful [28]. In a patient
carrying mutations, the cumulative risk of aHUS is around 18% [25].
It is important to highlight that a pregnancy-related aHUS can
relapse independently to pregnancy.
Differential diagnosis of thrombocytopenia in pregnancy and
recognition of TMAs
Clinical recognition of any TMA requires the documentation
of MAHA. These laboratory changes very often occur concomi-
tantly with clinical involvement of at least an organ system.
Blood test abnormalities and clinical symptoms TMAs-related
are summarized in Fig. 1.
Thrombocytopenia represents the second most common
finding after anemia during complete blood count (CBC) in
pregnant woman.
Most of thrombocytopenia cases (70–80%) are gestational
thrombocytopenias and deserve no special management, but in
presence of an abnormal peripheral blood smear and hemolysis
markers further investigation is deemed, as this finding could be
associated with a TMA such as HELLP syndrome, TTP or aHUS.
Disseminated Intravascular Coagulation (DIC), usually secondary
to infection or malignancy, stands apart from the other TMAs because
it has characteristic laboratory abnormalities indicative of a consump-
tive coagulopathy, including an elevated international normalized
ratio (INR) and activated partial thromboplastin time (aPTT).
TMAs due to autoimmune diseases are primarily recognized by
the presence of a positive Direct Coombs Test (DCT) [31]. Those TMAs
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Systemic Lupus Erythematosus (SLE), Scleroderma or Anti-Neutro-
phil Cytoplasmic Antibodies (ANCA)-Vasculitis. If those signs and
symptoms of TMA do not resolve once the identified condition has
been treated, it has to be considered that the primary disease may
have unmasked aHUS or TTP and, therefore, undertake appropriate
diagnostic procedures to investigate that possibility [23].Fig. 2. Simplified flow chart for differential diagnosis of thrombocytopenia in pregnan
CBC (cell blood count); LFT (liver function test).HELLP or a different TMA?
Generally, post-partum full rapid recovery is the rule for HELLP,
but therapeutic intervention is needed when hemolysis, throm-
bocytopenia or renal failure continue to worsen after 48–72 hrs
postpartum. It is important to consider TPP or aHUS in the
differential diagnosis of HELLP non recovering spontaneously aftercy and specific management of pregnancy-related TMAs.
L. Sarno et al. / European Journal of Obstetrics & Gynecology and Reproductive Biology 237 (2019) 7–12 1148–72 h with one or multi-organ involvement, and provide
appropriate treatment such as complement inhibitor in case of
ADAMTS-13 activity level above 5–10% and no overt Disseminated
Intravascular Coagulation [32].
Moreover, aHUS is mainly characterized by an acute renal
failure and hemolysis, with elevated serum creatinine level
(>2 mg/dl) and elevated LDH values (>1000 U/l), while these
parameters are less abnormal in HELLP syndrome [23].
ADAMTS-13 testing is very relevant in management decision
for TMAs, as it has been recently shown that Therapeutic Plasma
Exchange (TPE) is not providing any morbidity and/or mortality
benefit if ADAMTS-13 is above 10%, and rapid ADAMTS-13 testing
results provide significant cost saving for the hospital due to
avoidance of unnecessary aphaeretic procedures for TMA
management [33].
Treatment of pregnancy-related TMAs
It is of essential importance to correctly identify TMAs in
pregnancy due to the specific management and treatment for each
condition. The American Society for Apheresis (ASFA) provides
evidence Category I, Recommendation Grade 1A for Therapeutic
Apheresis only for the management of TPP while, in other TMAs,
TPE may be ineffective or even harmful and these conditions have
been designated Category IV indications for TPE in the current
ASFA guidelines [34].
Scully et al [35] have reported five successful pregnancies and
deliveries in the third trimester after regular plasma exchange and
low molecular weight heparin treatment in patients with history of
TTP and very poor neonatal outcome in previous pregnancies. Of
note, one patient was treated also with rituximab (a humanized
monoclonal antibody against B-cell surface antigen CD20). Subse-
quently, the same author reported obstetrical and neonatal outcome
in a prospective studyof TTP cases from the UK TTP registry. Fetal loss
occurred in 16/38 pregnancies before cTTP was diagnosed, but in
none of the 15 subsequent managed pregnancies [18].
It has to be reminded that TPE is a lifesaving procedure in cases
of TPP, but is also invasive, with significant risk of complications,
therefore TPE necessitates thoughtful reservation concerning its
use as an emergent treatment modality.
Plasmapheresis can be only temporarily or partially effective in
the majority of cases of aHUS, with no recovery of renal function in
up to 80% of cases [26].
Eculizumab has been approved for treatment of aHUS and
paroxysmal nocturnal haemoglobinuria (PNH). It is a humanized
IgG2/4 kappa anti-C5 antibody and acts by blocking the enzymatic
cleavage of C5 to C5a and C5b.
It is a major step forward in the treatment of aHUS patients,
acting to block complement-mediated inflammation and endo-
thelial damage and leading to a reduction of need for blood
transfusions and improving the prognosis [23]. As an example, in
the Spanish cohort with pregnancy associated aHUS, seventeen
patients underwent plasma treatments with only three having a
positive response while ten patients received eculizumab with an
excellent renal response in all, independent of carrying or not
inherited complement abnormalities [24].
Data on its use during pregnancy are still limited, even if
according to reported evidences it seems to be safe for fetus and
newborn. Higher doses and/or more frequent eculizumab infusions
may be required in some patients to achieve rapid and complete
complement inhibition [36].
There is only one case report on eculizumab use in pregnancy
with HELLP, although it has not been officially approved for this
indication. Prolongation of pregnancy from 26 + 3 to 28 + 6 (17 days)
was achieved [37]. There is a considerable neonatal outcome
improvement for each week of gestation in this group of patients,especially when timing of antenatal steroids and magnesium
sulphate neuroprotection is optimal. Although the expectant
management in pregnancies with HELLP may gain few days and
slightly improve the neonatal outcome, it can be associated with
severe maternal complications. Therefore, in most of the cases
prompt delivery is indicated. It might be possible that in the near
future, eculizumab will be a drug of choice for selected pregnant
women with the clear signs of complement activation.
Fig. 2 displays flow chart summarizing the clues for differential
diagnosis and management in case of thrombocytopenia in
pregnancy.
Conclusions
Pregnancy is a condition that itself amplify complement activity
and can unmask TMAs [23,32].
TMAs different from HELLP syndrome should be suspected
always when recovery of clinical and serological conditions after
delivery does not occur.
Improvements of clinical conditions, resolution of headache,
visual symptoms, abdominal pain, increasing platelet counts and
resolution of MAHA after delivery allows us to exclude TTP or
aHUS. Worsening of thrombocytopenia 72 h after delivery is
suggestive of TTP, while increasing serum creatinine is more
specific for aHUS.
Suspicion of TTP or aHUS is fundamental to avoid delay in
treatment that can lead to irreversible renal failure or sudden
death. Although the obstetricians are usually in the first line of
handling these conditions and the awareness of these conditions is
prerequisite for the recognition and treatment of TMAs, the
multidisciplinary involvement is of essential importance. Eculi-
zumab, as a novel treatment has been approved for aHUS
treatment, but it may be feasible also in selected HELLP cases
with the clear evidence of the complement activation. Due to the
cost of eculizumab, it is unlikely that randomized trials will be soon
conducted, but we hope that more case reports will be emerging in
the near future.
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